Israel Ben-yoram is Director at PLURISTEM THERAPEUTICS INC (PSTI). They have made 11 open-market trades across 1 company since 2008, most recently 2019-04-08.
CIK 0001320556
7 open-market purchases totalling $390K since 2008, against 4 sales. Across 7 scored buys the stock is up 6.6% at ninety days, and 4.8 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| PSTI | 387,235 | $387K |
Shares reported on the most recent Form 4, priced at the 2019-04-08 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 14% | 100% | 86% |
| Avg Move | -16.4% | +7.4% | +6.6% |
| Alpha | -12.6% | +6.2% | +4.8% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PSTI | BUY | 2019-04-08 | 2019-04-08 | $0.70 | $100K | -15.6% | +8.4% | -3.8% |
| PSTI | BUY | 2016-02-11 | 2016-02-16 | $0.79 | $8K | +8.7% | +29.6% | +36.5% |
| PSTI | SELL | 2015-09-21 | 2015-09-24 | $2.10 | $63K | -21.5% | +2.7% | +2.7% |
| PSTI | BUY | 2015-09-21 | 2015-09-24 | $2.09 | $63K | -21.5% | +2.7% | +2.7% |
| PSTI | BUY | 2014-09-17 | 2014-09-18 | $2.82 | $14K | -21.5% | +2.7% | +2.7% |
| PSTI | SELL · 10b5-1 | 2014-01-16 | 2014-01-21 | $4.51 | $161K | -21.5% | +2.7% | +2.7% |
| PSTI | SELL · 10b5-1 | 2014-01-10 | 2014-01-14 | $4.30 | $114K | -21.5% | +2.7% | +2.7% |
| PSTI | SELL · 10b5-1 | 2014-01-07 | 2014-01-09 | $4.12 | $185K | -21.5% | +2.7% | +2.7% |
| PSTI | SELL | 2013-09-12 | 2013-09-16 | $3.08 | $157K | -21.5% | +2.7% | +2.7% |
| PSTI | BUY | 2013-05-16 | 2013-05-21 | $3.04 | $194K | -21.5% | +2.7% | +2.7% |
| PSTI | SELL | 2013-05-16 | 2013-05-21 | $3.03 | $138K | -21.5% | +2.7% | +2.7% |
| PSTI | SELL | 2009-12-28 | 2009-12-29 | $1.13 | $6K | -21.5% | +2.7% | +2.7% |
| PSTI | BUY | 2009-12-28 | 2009-12-29 | $1.13 | $6K | -21.5% | +2.7% | +2.7% |
| PSTI | BUY | 2008-06-24 | 2008-07-03 | $1.98 | $5K | -21.5% | +2.7% | +2.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.